
FDA aligns with Cognition on a phase 3 zervimesine trial for Lewy body dementia, testing 100 mg daily for 9 months to target hallucinations.
How is the Sigourney Award helping expand the boundaries of psychoanalytic thinking?
In this Mental Health Minute video, Heidi Anne Duerr, MPH, associate editorial director of Psychiatric TimesTM, interviews William A. Myerson, PhD, MBA, co-trustee of the Sigourney Award and training and supervising analyst at the Center for Psychanalytic Studies, about how the Sigourney Award is advancing psychoanalytic thought worldwide.
Dr Myerson is a co-trustee of the






